Drug Profile
Z 100
Alternative Names: Ancer20; SSM; Z-100Latest Information Update: 14 Mar 2022
Price :
$50
*
At a glance
- Originator Zeria
- Class Anti-inflammatories; Antineoplastics; Antivirals; Esters; Lipids; Mannans
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Leucopenia
- Phase III Cervical cancer
- Discontinued HIV infections; Rheumatoid arthritis
Most Recent Events
- 25 Feb 2022 Zeria Pharmaceutical completes phase III trials for Cervical cancer (First-line therapy, Late-stage disease) in Japan, South Korea, Malaysia, Singapore, Taiwan, Thailand and Vietnam (NCT02247232)
- 08 Apr 2021 Z 100 is still in phase III trials for Cervical cancer in theJapan, Malaysia, Singapore, South Korea, Taiwan,Thailand and Vietnam (March 2021, Zeria Pharmaceutical pipeline)
- 02 Apr 2018 Zeria Pharmaceutical initiates enrolment in a phase III trial in Cervical cancer (Late-stage disease, First line therapy) in Vietnam (SC) (NCT03476018)